CJ Bioscience Challenges Global Microbiome Analysis Service

Published 28 Jul.2023 08:51(KST)

CJ CheilJedang's independent red bio (pharmaceutical? healthcare) subsidiary, CJ Bioscience, has launched an initiative to target the global microbiome analysis service market.

At the workshop held on the 26th for utilizing the 'EasyBiome Bioinformatics App,' Cheon Jong-sik, CEO of CJ Bioscience, is delivering the welcome address. Photo by CJ Bioscience

On the 26th, CJ Bioscience held a workshop at its headquarters in Jung-gu, Seoul, regarding the use of the global premium microbiome analysis platform, tentatively named 'EzBiome Bioinformatics App,' the company announced on the 28th.

The event, themed "EzBiome for Microbiome Data Utilization," was attended by over 60 participants including key opinion leaders (KOLs) in microbiology, university hospitals, research institutions, and industry stakeholders. The program included presentations on microbial identification and platform utilization cases in clinical and diagnostic fields, introductions and demonstrations of premium analysis service features, and case studies.

EzBiome is a software-as-a-service (SaaS) microbial bioinformatics analysis platform. CJ Bioscience has enhanced the functionality of its currently operated 'EzBioCloud' platform to extend its use to clinical and infectious disease diagnostics, while advancing the microbiome database to enable rapid analysis of large-scale data from anywhere in the world. Notably, it allows customers to generate analysis results tailored to their specific research fields, thereby improving the accuracy and speed of research.

Since this month, CJ Bioscience has been conducting a pilot service by opening some features to bio industry stakeholders and university professors, incorporating expert feedback with plans to officially launch the service next year. Upon official launch, the company is also considering employing artificial intelligence (AI) to analyze microbiome genomes, aiming to lead the global microbial data analysis market and create new revenue streams.

A CJ Bioscience representative stated, “With the recent expansion of genome analysis services in hospitals and other institutions, demand in clinical and infectious disease diagnostics is increasing, and the related market is expected to continue growing. We will provide a premium service of the highest global standard based on our advanced microbiome data analysis technology.”